Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 24, 2021 17:15 ET | Source: Allarity Therapeutics A/S

Allarity Therapeutics A/S Publishes Offer Document Offering to Acquire Company Shares in Exchange for Shares in Allarity Therapeutics, Inc. with the Intent to Complete Recapitalization

Press release Hørsholm, Denmark (November 24, 2021) — Allarity Therapeutics A/S ("Allarity A/S" or the "Company") hereby announces a voluntary offer and offer document to the shareholders of...
November 24, 2021 15:50 ET | Source: Allarity Therapeutics A/S

Grant of New Warrants and Resolutions on Existing Warrants

Company Announcement Hørsholm, Denmark (November 24, 2021) — Allarity Therapeutics A/S ("Allarity" or the "Company") today announced that the Board of Directors of Allarity has exercised the...
November 23, 2021 02:00 ET | Source: Allarity Therapeutics A/S

Allarity Therapeutics Publishes Interim Report for the Period January – September 2021

Press Release Hørsholm, Denmark (November 23, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announces the publication of its Interim Report for the period January – September...
November 22, 2021 18:00 ET | Source: Allarity Therapeutics A/S

Minutes of Extraordinary General Meeting held on 22 November 2021

Company Announcement Minutes of Extraordinary General Meeting held on 22 November 2021The English part of this parallel document in Danish (attached) and English is an unofficial translation of the...
November 11, 2021 02:30 ET | Source: Allarity Therapeutics A/S

Allarity Therapeutics’ Oral PARP Inhibitor, Stenoparib, Demonstrates Pre-clinical Antiviral Activity Against Delta Variant of Coronavirus

Current positive results with delta variant B.1.617.2 follows previous pre-clinical tests, including testing of alpha variant B.1.1.7 (“British” variant),beta variant B.1351 (“South African” variant),...
November 05, 2021 17:11 ET | Source: Allarity Therapeutics A/S

NOTICE OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF ALLARITY THERAPEUTICS A/S TO BE HELD ON NOVEMBER 22, 2021

Press release THE BOARD OF DIRECTORS HEREBY CONVENES an extraordinary general meeting of the shareholders of Allarity Therapeutics A/S (“Allarity A/S”) to be held on November 22, 2021 at 10:00 am...
November 05, 2021 16:48 ET | Source: Allarity Therapeutics A/S

U.S. SEC Issues Order Declaring Allarity Therapeutics Inc.’s Form S-4 Registration Statement Effective Ahead of Planned Transition to U.S. Nasdaq

An application for listing on the U.S. Nasdaq Stock Market for the shares of Allarity Therapeutics, Inc. (Delaware) (Nasdaq: ALLR) has been made conditioned upon shareholder approval of the...
September 23, 2021 03:00 ET | Source: Allarity Therapeutics A/S

Allarity Therapeutics and Lonza Collaborate to Manufacture Dovitinib, a Renal Cell Carcinoma Candidate

Integrated solution for process development and manufacturing of drug substance and drug product will facilitate the advancement of clinical developmentThe agreement meets Allarity’s needs for...
September 16, 2021 04:00 ET | Source: Allarity Therapeutics A/S

Allarity Therapeutics Presents Dovitinib Survival Data from DRP® Screened RCC Patients at ESMO 2021 Virtual Congress

Patient selection using DRP® score of 50% resulted in a median survival of 15.0 monthPatient selection using DRP® score of 67% resulted in a median survival of 20.6 months Press Release Hørsholm,...
September 15, 2021 17:55 ET | Source: Allarity Therapeutics A/S

Update: Allarity Therapeutics Receives Approximately SEK 23.3 Million (US $2.7 Million) from Subscription to Warrants of Series ALLR TO 2 and TO 3

Subscription is approximately 9.5 percent of total outstanding TO 3 warrants Allarity’s Chairman of the Board and largest shareholder (Sass & Larsen ApS) participated in the subscription Press...